Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesDividends payablesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Envoy Medical (COCH) Cash & Equivalents (2022 - 2025)

Envoy Medical's Cash & Equivalents history spans 4 years, with the latest figure at $3.7 million for Q4 2025.

  • Quarterly results put Cash & Equivalents at $3.7 million for Q4 2025, down 31.81% from a year ago — trailing twelve months through Dec 2025 was $3.7 million (down 31.81% YoY), and the annual figure for FY2025 was $3.7 million, down 31.81%.
  • Cash & Equivalents for Q4 2025 was $3.7 million at Envoy Medical, up from $3.6 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $16.8 million in Q3 2023 to a low of $68000.0 in Q2 2023.
  • The 4-year median for Cash & Equivalents is $3.7 million (2025), against an average of $3.8 million.
  • Peak annual rise in Cash & Equivalents hit 5476.21% in 2023, while the deepest fall reached 85.74% in 2023.
  • Year by year, Cash & Equivalents stood at $183000.0 in 2022, then surged by 2205.46% to $4.2 million in 2023, then grew by 29.96% to $5.5 million in 2024, then tumbled by 31.81% to $3.7 million in 2025.
  • According to Business Quant data, Cash & Equivalents over the past three periods came in at $3.7 million, $3.6 million, and $5.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.